◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › LLY

Eli Lilly and Company (LLY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Pharmaceuticals · DATA UPDATED 2026-07-10

Eli Lilly and Company (LLY) operates in the Pharmaceuticals industry and is headquartered in Indianapolis, United States with about 50,000 employees. Its market capitalization is roughly $1.07 trillion. In the fiscal year ended 2025-12-31, LLY reported $65.2B in revenue and $20.6B in net income.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

Interactive charts & full statements → Open the LLY valuation workbench →

LLY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$72.2B	$65.2B	$45.0B	$34.1B	$28.5B	$28.3B	$24.5B	$22.3B	$21.5B	$20.0B	$21.2B	$20.0B	$19.6B	$23.1B	$22.6B	$24.3B	$23.1B	$21.8B	$20.4B	$18.6B	$15.7B
Gross Profit	$60.3B	$54.6B	$36.6B	$27.0B	$21.9B	$21.0B	$19.1B	$17.6B	$16.8B	$15.5B	$15.5B	$14.9B	$14.7B	$18.2B	$17.8B	$19.2B	$18.7B	$17.6B	$16.0B	$14.4B	$12.1B
Gross Margin %	83.5%	83.8%	81.3%	79.2%	76.8%	74.2%	77.7%	78.8%	78.2%	77.7%	73.1%	74.8%	74.9%	78.8%	78.8%	79.1%	81.1%	80.5%	78.5%	77.2%	77.4%
Operating Income (EBIT)	$33.1B	$29.7B	$17.5B	$10.8B	$8.7B	$7.9B	$7.2B	$6.0B	$6.0B	$4.2B	$3.9B	$3.6B	$3.3B	$5.5B	$5.0B	$6.3B	$6.8B	$6.4B	$5.5B	$4.8B	$4.1B
Operating Margin %	45.9%	45.6%	38.9%	31.6%	30.3%	28.0%	29.4%	26.9%	28.0%	21.3%	18.2%	18.0%	17.0%	24.0%	22.2%	26.0%	29.3%	29.2%	27.1%	25.8%	26.3%
Net Income	$25.3B	$20.6B	$10.6B	$5.2B	$6.2B	$5.6B	$6.2B	$8.3B	$3.2B	($204M)	$2.7B	$2.4B	$2.4B	$4.7B	$4.1B	$4.3B	$5.1B	$4.3B	($2.1B)	$3.0B	$2.7B
Net Margin %	35.0%	31.7%	23.5%	15.4%	21.9%	19.7%	25.2%	37.3%	15.0%	-1.0%	12.9%	12.1%	12.2%	20.3%	18.1%	17.9%	22.0%	19.8%	-10.2%	15.8%	17.0%
EBITDA	$33.5B	$27.9B	$15.2B	$8.6B	$8.7B	$8.0B	$8.9B	$6.9B	$5.5B	$4.1B	$5.1B	$4.4B	$4.5B	$7.5B	$7.0B	$6.9B	$8.0B	$6.9B	$43M	$5.9B	$4.9B
Earnings Per Share (EPS)	$28.15	$22.98	$11.71	$5.80	$6.57	$5.85	$6.47	$8.69	$3.13	$-0.19	$2.49	$2.18	$2.15	$4.19	$3.57	$3.90	$4.58	$3.94	$-1.89	$2.71	$2.45
Shares Outstanding (M)	896M	898M	904M	903M	950M	954M	957M	958M	1,034M	1,052M	1,101M	1,105M	1,111M	1,117M	1,146M	1,114M	1,106M	1,098M	1,094M	1,091M	1,087M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LLY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$19.8B	$19.3B	$17.6B	$15.6B	$12.7B	$13.5B	$11.4B	$11.3B
Gross Profit	$16.2B	$16.4B	$14.6B	$13.1B	$10.5B	$11.1B	$9.3B	$9.1B
Gross Margin %	81.9%	85.0%	82.9%	84.3%	82.5%	82.2%	81.0%	80.8%
Operating Income (EBIT)	$8.8B	$8.8B	$8.4B	$7.1B	$5.4B	$5.8B	$4.5B	$4.4B
Operating Margin %	44.7%	45.5%	47.6%	45.8%	42.5%	42.8%	39.8%	39.1%
Net Income	$7.4B	$6.6B	$5.6B	$5.7B	$2.8B	$4.4B	$970M	$3.0B
Net Margin %	37.4%	34.4%	31.7%	36.4%	21.7%	32.6%	8.5%	26.2%
EBITDA	$9.7B	$8.4B	$7.9B	$7.5B	$4.2B	$5.7B	$2.2B	$4.1B
Earnings Per Share (EPS)	$8.26	$7.39	$6.21	$6.29	$3.06	$4.88	$1.07	$3.28
Shares Outstanding (M)	896M	898M	899M	900M	901M	903M	905M	904M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LLY Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$20.5B	$16.8B	$8.8B	$4.2B	$7.1B	$7.3B	$6.5B	$4.8B	$5.5B	$5.6B	$4.9B	$3.0B	$4.5B	$5.7B	$5.3B	$7.2B	$6.9B	$4.3B	$7.3B	$5.2B	$4.0B
Capital Expenditures (CapEx)	$6.9B	$7.8B	$8.4B	$7.4B	$2.5B	$1.9B	$2.0B	$1.4B	$3.0B	$2.2B	$1.1B	$1.6B	$1.6B	$1.1B	$1.0B	$1.7B	$1.2B	$855M	$947M	$1.1B	$1.1B
Free Cash Flow (FCF)	$13.6B	$9.0B	$414M	($3.2B)	$4.6B	$5.4B	$4.5B	$3.5B	$2.5B	$3.5B	$3.8B	$1.3B	$2.9B	$4.6B	$4.3B	$5.5B	$5.7B	$3.5B	$6.3B	$4.1B	$2.9B
FCF Margin %	18.8%	13.8%	0.9%	-9.2%	16.1%	19.0%	18.2%	15.6%	11.7%	17.3%	17.7%	6.7%	14.8%	20.1%	18.9%	22.8%	24.6%	15.9%	31.2%	21.9%	18.5%
Dividends Paid	$5.6B	$5.4B	$4.7B	$4.1B	$3.5B	$3.1B	$2.7B	$2.4B	$2.3B	$2.2B	$2.2B	$2.1B	$2.1B	$2.1B	$2.2B	$2.2B	$2.2B	$2.2B	$2.1B	$1.9B	$1.7B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LLY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$5.3B	$3.2B	$8.8B	$3.1B	$1.7B	$2.5B	$3.7B	$1.5B
Capital Expenditures (CapEx)	$2.3B	$2.5B	$224M	$1.8B	$3.3B	$1.7B	$4.2B	$1.4B
Free Cash Flow (FCF)	$3.0B	$678M	$8.6B	$1.3B	($1.6B)	$727M	($459M)	$63M
FCF Margin %	15.2%	3.5%	48.9%	8.2%	-12.6%	5.4%	-4.0%	0.6%
Dividends Paid	$1.5B	$1.3B	$1.3B	$1.3B	$1.3B	$1.2B	$1.2B	$1.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LLY Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$116.6B	$112.5B	$78.7B	$64.0B	$49.5B	$48.8B	$46.6B	$39.3B	$43.9B	$45.0B	$38.8B	$35.6B	$36.3B	$35.2B	$34.4B	$33.7B	$31.0B	$27.5B	$29.2B	$26.8B	$22.0B
Cash & Cash Equivalents	$5.1B	$7.2B	$3.3B	$2.8B	$2.1B	$3.8B	$3.7B	$2.3B	$7.3B	$6.5B	$4.6B	$3.7B	$3.9B	$3.8B	$4.0B	$5.9B	$6.0B	$4.5B	$5.5B	$3.2B	$3.1B
Total Liabilities	$85.4B	$85.9B	$64.4B	$53.1B	$38.7B	$39.7B	$40.8B	$36.6B	$33.0B	$33.3B	$24.7B	$21.0B	$20.9B	$17.6B	$19.6B	$20.1B	$18.6B	$17.9B	$22.5B	$13.4B	$11.0B
Total Debt (Short + Long-Term)	$43.4B	$42.5B	$33.6B	$25.2B	$16.2B	$16.9B	$16.6B	$15.3B	$12.7B	$13.6B	$10.3B	$8.0B	$8.1B	$5.2B	$5.5B	$7.0B	$6.9B	$6.7B	$10.5B	$5.0B	$3.7B
Total Shareholders' Equity	$31.2B	$26.5B	$14.2B	$10.8B	$10.7B	$9.0B	$5.6B	$2.6B	$10.9B	$11.6B	$14.0B	$14.6B	$15.4B	$17.6B	$14.8B	$13.5B	$12.4B	$9.5B	$6.7B	$13.5B	$11.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LLY viewer.

Other Companies in Pharmaceuticals

JNJ · Johnson & Johnson — $635 billion
MRK · Merck & Co. — $324 billion
PFE · Pfizer — $140 billion
BMY · Bristol Myers Squibb — $127 billion
ZTS · Zoetis — $32 billion
VTRS · Viatris — $20 billion

← LKSP All stocks LLYVA →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.